Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
Belimumab is approved for the treatment of active systemic lupus erythematosus. BASE was a double-blind, randomised, placebo-controlled, phase 4 trial done in 33 countries. Ten patients in the belimumab group died versus eight in the placebo group.
